Sensorineural deafness with dilated cardiomyopathy Advocacy Hub | UniteRare

At a Glance

Live from database

💊

2FDA treatments

💰

1Open funds

Regulatory Watchboard

1 event

Apr 2019

CORLANOR: FDA approved

Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

CORLANOR

Amgen, Inc.,

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

CORLANOR

(ivabradine)Orphan drug

Amgen, Inc.,

12.1 Mechanism of Action Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I...

Approved Apr 2019FDA label ↗

Aminocaproic Acid

(AMINOCAPROIC ACID)Orphan drugstandard

American Regent, Inc.

Antifibrinolytic Agent [EPC]

FDA label ↗

View full treatment details on disease page →